Section of Dermatology and Venereology, Department of Medicine, University of Verona , Verona , Italy.
Section of Rheumatology, University of Verona , Verona , Italy.
Front Med (Lausanne). 2015 Jan 21;2:1. doi: 10.3389/fmed.2015.00001. eCollection 2015.
Psoriasis is a chronic inflammatory skin disease affecting 2-3% of worldwide population. The extent of skin involvement is variable, ranging from a few localized plaques to generalized involvement. Moderate to severe psoriasis (>10% of body surface area) is frequently associated with psoriatic arthritis and metabolic diseases, like abdominal obesity, diabetes, non-alcoholic fatty liver disease, dyslipidemia, metabolic syndrome, and chronic kidney disease. A common genetic background as well as several acquired risk factors links psoriasis to comorbidities. From a clinical prespective, the understanding of the patients in the context of these comorbidities is very important to ensure that treatment is tailored to meet the individual patient needs. Indeed, some pharmacological treatments may negatively affect cardio-metabolic comorbidities, and have important interactions with drugs that are commonly used to treat them. Non-pharmacological intervention such as diet, smoking cessation, and physical exercise could both improve the response to treatments for psoriasis and reduce the cardiovascular risk.
银屑病是一种慢性炎症性皮肤病，影响全球 2-3%的人口。皮肤受累的程度各不相同，从少数局部斑块到广泛受累。中度至重度银屑病（>10%的体表面积）常与银屑病关节炎和代谢性疾病相关，如腹型肥胖、糖尿病、非酒精性脂肪性肝病、血脂异常、代谢综合征和慢性肾脏病。常见的遗传背景和多种获得性危险因素将银屑病与合并症联系起来。从临床角度来看，了解患者的这些合并症非常重要，以确保治疗方案能够满足个体患者的需求。事实上，一些药物治疗可能会对心血管代谢合并症产生负面影响，并与常用于治疗这些合并症的药物有重要的相互作用。非药物干预，如饮食、戒烟和体育锻炼，既能改善银屑病的治疗反应，又能降低心血管风险。
